A Nevada federal court recently ruled in favor of Ferring Pharmaceuticals, Inc. in an abbreviated new drug application (ANDA) patent infringement trial. Following a bench trial, the court found “Ferring’s patents were valid and infringed by both Watson and Apotex.” In a statement, Ferring president and chief operating officer, Aaron Graff said, “Ferring has been 100 percent committed to protecting our intellectual property, and we are pleased by the outcome.” Finnegan represented Ferring in this matter.